MedDataX Logo

Once Daily vs Twice Daily Administration of Gonadotropins in Assisted Reproductive Technologies (ART)

NCT ID: NCT00740025

Last Updated: 2010-10-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-01-31

Study Completion Date

2010-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective randomized study evaluating dosing frequency of gonadotropin administration in ART cycles.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Using once daily or bid dosing of gonadotropins in ART has been arbitrary with no studies showing whether splitting the medication dose improves ART parameters. This study was undertaken to provide an answer to this important question.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pregnancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

QD

Women who received their meds as QD administration

No interventions assigned to this group

BID

Women who received their gonadotropins as a BID dose

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* women \< 40 undergoing ART

Exclusion Criteria

* women \> 40
* endometriomas
* severe cervical stenosis
* testicular sperm
Minimum Eligible Age

21 Years

Maximum Eligible Age

39 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Virginia Center for Reproductive Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Virginia Center for Reproductive Medicine

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Fady I Sharara, M.D

Role: PRINCIPAL_INVESTIGATOR

Virginia Center for Reproductive Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Virginia Center for Reproductive Medicine

Reston, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1-Sharara

Identifier Type: -

Identifier Source: org_study_id